Abstract:Feng Hu, 1, 2, &ast Zilu Qu, 1, 2, &ast Kai Chen, 1, 2 Ping Zhang, 1 Bei Wang, 1 Ruili Jiang, 1 Yuyue Zuo, 1 Ping Xia, 1, &ast Hongxiang Chen 3, 4, &ast 1 Department of Dermatology, Wuhan No. 1 Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People's Republic of China; 2 Hubei Province & Key Laboratory of Skin Infection and Immunity, Wuhan No. 1 Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People's Republic of China; 3 Department of Dermatology, Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen, 518052, People's Republic of China; 4 Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People's Republic of China &astThese authors contributed equally to this work Correspondence: Hongxiang Chen, Huazhong University of Science and Technology Union Shenzhen Hospital, No. 89, Taoyuan Road, Nanshan District, Shenzhen, 518052, People's Republic of China, Tel +86 13871022932, Email Ping Xia, Email Introduction: As a mediator of inflammation resolution, lipoxin A4 (LXA4) mainly plays an anti-inflammatory role and promotes inflammation resolution. LXA4 plays an inhibiting inflammatory role in a variety of diseases, tissues and cells, including keratinocytes. Psoriasis is a chronic inflammatory skin disease mediated by dysregulation of inflammation of immune cells and keratinocytes. However, the expression and role of LXA4 in psoriasis-like mouse models are still unclear. Methods: Imiquimod (IMQ) topical treatment of dorsal skin induces psoriasis-like dermatitis in BALB/c mice, pretreated intraperitoneally with or without LXA4 prior to IMQ application. Severity of dorsal lesions is assessed by using a modified human scoring system and histopathology. The concentration of LXA4 and the expression of ALOX15 (a key gene in LXA4 metabolic synthesis) in lesional skins were detected by ELISA and Western blot. Quantitative PCR and ELISA were conducted to detect the mRNA and secretion levels of inflammatory cytokines. The proportion of IL-17A-producing γδT cells in skin and skin draining cervical lymph nodes and helper (Th) 17 cells in spleens was evaluated by flow cytometry. Western blotting was used to analyze the expressions of p-STAT3 and TRAF6. Results: The concentration of LXA4 and the expression of ALOX15 were decreased in IMQ-induced lesional skin. LXA4 significantly relieved psoriasis-like lesions in IMQ-induced mouse models. Furthermore, LXA4 decreased IMQ-induced systemic inflammation, including reduced the proportion of IL-17A-producing gdT cells in skin and skin draining cervical lymph nodes and Th17 cells in spleens, the secretion and expression of CCL20, IL-17A, IL-1β, and TNF-α in skin and serum. LXA4 markedly inhibited IMQ-induced expression of TRAF6 and p-STAT3. Conclusion: LXA4 significantly ameliorates IMQ-induced psoriasis-like inflammation, and LXA4 can be used as a target for psoriasis treatment. Keywords: lipoxin A4, psoriasiform dermatitis, imiquimod, γδT cells, Th17, inflammation Psoriasis is manifested by excessive hyperplasia of keratinocytes of the epidermis, accompanied by extensive infiltration of inflammatory cells into the epidermis and dermis. Typical histologic features include hyperkeratosis, parakeratosis, and formation of neutrophil microabscesses (also known as Munro microabscesses) in the areas of parakeratosis; the granular layer is significantly reduced or disappeared, the muscular layer above the dermal papilla becomes thinner, with elongated capillaries, and clinical manifestations of erythema, scaling, and thickening. 1 The IL-23/IL-17 cytokine axis plays a central role in the development and progression of psoriasis. 2,3 Biologics and small molecule drugs targeting IL-23/IL-17 cytokine axis have made great progress in the treatment of psoriasis in recent years. 4 Imiquimod (IMQ) is a small molecule immunomodulator, an antagonist of Toll-like receptor (TLR) 7/8, and is clinically used to treat genital warts caused by human papillomavirus infection. IMQ activates monocytes, macrophages and dendritic cells to produce multiple cytokines including IFN-α, TNF-α, IL-2, IL-6, which mediate antiviral effects. IMQ application to mouse skin induces the similar clinical and histological features to human psoriasis and has been widely used to explore the pathogenesis of psoriasis. 5,6 It was reported that IMQ-induce psoriasis-lik -Abstract Truncated-

Tranexamic acid improves psoriasis-like skin inflammation: Evidence from in vivo and in vitro studies

L-Theanine Alleviates IMQ-Induced Psoriasis Like Skin Inflammation by Downregulating the Production of IL-23 and Chemokines

Tranexamic Acid Ameliorates Skin Hyperpigmentation by Downregulating Endothelin-1 Expression in Dermal Microvascular Endothelial Cells

Tryptanthrin ameliorates imiquimod-induced psoriasis in mice by suppressing inflammation and oxidative stress via NF-κB/MAPK/Nrf2 pathways

Lipoxin A4 Ameliorates Imiquimod-Induced Psoriasis-Like Dermatitis via Promoting the Regression of Inflammation

Tetrastigma hemsleyanum polysaccharides alleviate imiquimod-induced psoriasis-like skin lesions in mice by modulating the JAK/STAT3 signaling pathway

Oral tranexamic acid treats papulopustular rosacea by improving the skin barrier

Tanshinone IIA, a component of the self‐made Xiao‐Yin decoction, ameliorates psoriasis by inhibiting IL‐17/IL‐23 and PTGS2/NF‐κB/AP‐1 pathways

Tranexamic acid ameliorates rosacea symptoms through regulating immune response and angiogenesis

Lipoxin A4 and Its Analog Suppress Inflammation by Modulating HMGB1 Translocation and Expression in Psoriasis

Thymopentapeptide Affects T-Cell Subsets by Modulating the Flora of the Skin Surface to Alleviate Psoriasis

Azithromycin impairs TLR7 signaling in dendritic cells and improves the severity of imiquimod-induced psoriasis-like skin inflammation in mice

Evidence on the therapeutic role of thiolutin in imiquimod‐induced psoriasis‐like skin inflammation in mice

Electroacupuncture and methotrexate cooperate to ameliorate psoriasiform skin inflammation by regulating the immune balance of Th17/Treg

Increased Βtrcp Are Associated with Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Via NF-κB Signaling Pathway

Quercetin Ameliorates Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Via the NF-κB Pathway.

Topical administration of reversible SAHH inhibitor ameliorates imiquimod-induced psoriasis-like skin lesions in mice via suppression of TNF-alpha/IFN-gamma-induced inflammatory response in keratinocytes and T cell-derived IL-17

Immune-protective effect of topical paquinimod administration against imiquimod-induced psoriasis-like inflammation in mice

Benzoylaconitine Alleviates Progression of Psoriasis via Suppressing STAT3 Phosphorylation in Keratinocytes

LY294002 ameliorates psoriatic skin inflammation in mice via blocking the Notch1/Hes1-PTEN/AKT/IL-17A feedback loop

18β-Glycyrrhetinic acid induces human HaCaT keratinocytes apoptosis through ROS-mediated PI3K-Akt signaling pathway and ameliorates IMQ-induced psoriasis-like skin lesions in mice